Protalix BioTherapeutics (PLX) SEC Filings & 10K Form $2.43 +0.05 (+2.10%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$2.43 0.00 (0.00%) As of 01/31/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share SEC Filings Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Recent Protalix BioTherapeutics SEC Filings All Filing Types 1 10 10-D 10-K 10-M 10-Q 11-K 12b-25 13F 13H 144 15 15F 17-H 18 18-K 19b-4(e) 19b-4 19b-7 1-A 1-E 1-K 1-N 1-SA 1-U 1-Z 20-F 24F-2 25 2-E 3 4 40-F 5 6-K 7-M 8-A 8-K 8-M 9-M ABS DD-15E ABS-15G ABS-EE ADV ADV-E ADV-H ADV-NR ADV-W ATS ATS-R BD BD-N BDW C CA-1 CB CFPORTAL D F-1 F-10 F-3 F-4 F-6 F-7 F-8 F-80 F-N F-X ID MA MA-I MA-NR MA-W MSD MSDW n/a N-14 N-17D-1 N-17f-1 N-17f-2 N-18f-1 N-1A N-2 N-23c-3 N-27D-1 N-3 N-4 N-5 N-54A N-54C N-6 N-6EI-1 N-6F N-8A N-8B-2 N-8B-4 N-8F N-CR N-CSR N-MFP N-PX N-Q NRSRO N-SAR PF PILOT R31 S-1 S-11 S-20 S-3 S-4 S-6 S-8 SBSE SBSE-A SBSE-BD SBSE-C SBSE-W SCI SD SDR SE SF-1 SF-3 SIP T-1 T-2 T-3 T-4 T-6 TA-1 TA-2 TA-W TCR TH WB-APP X-17A-19 X-17A-5 Part I X-17A-5 Part II X-17A-5 Part IIA X-17A-5 Part IIB X-17A-5 Part III X-17A-5 Schedule I X-17F-1A Filing Types Include Ownership Filings Exclude Ownership Filings Only Show Ownership FIlings Ownership Filings Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel DateFilerForm TypeView12/31/20243:30 PMProtalix BioTherapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 12/23/20246:01 AMProtalix BioTherapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 11/14/20246:03 AMProtalix BioTherapeutics (Filer)Form 10-QGeneral form for quarterly reports under Section 13 or 15(d) 11/14/20245:57 AMProtalix BioTherapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 11/05/20244:00 PMProtalix BioTherapeutics (Issuer)Rubin Eyal (Reporting)Form 4/A10/25/20243:23 PMProtalix BioTherapeutics (Subject)WHITEBOX ADVISORS LLC (Filed by)Form SC 13G/A10/25/20247:27 AMProtalix BioTherapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 09/24/20244:00 PMNaos Yaron (Reporting)Protalix BioTherapeutics (Issuer)Form 4Statement of changes in beneficial ownership of securities 09/24/20244:00 PMProtalix BioTherapeutics (Issuer)Rubin Eyal (Reporting)Form 4Statement of changes in beneficial ownership of securities 08/14/20246:02 AMProtalix BioTherapeutics (Filer)Form 10-QGeneral form for quarterly reports under Section 13 or 15(d) 08/14/20245:56 AMProtalix BioTherapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 05/10/20246:20 AMProtalix BioTherapeutics (Filer)Form 10-QGeneral form for quarterly reports under Section 13 or 15(d) 05/10/20245:59 AMProtalix BioTherapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) 04/03/20244:30 PMBashan Dror (Reporting)Protalix BioTherapeutics (Issuer)Form 4Statement of changes in beneficial ownership of securities 03/14/20246:03 AMProtalix BioTherapeutics (Filer)Form 10-KAnnual report pursuant to Section 13 or 15(d) 03/14/20245:57 AMProtalix BioTherapeutics (Filer)Form 8-KCurrent report pursuant to Section 13 or 15(d) (Data available from 1/1/2016 forward) Related Companies and Tools Related Companies LENZ SEC Filings PLRX SEC Filings VERV SEC Filings DNA SEC Filings IMTX SEC Filings ABUS SEC Filings CRGX SEC Filings DNTH SEC Filings OPT SEC Filings TECX SEC Filings SEC Filings Tools Latest SEC FilingsInsider Trading Activity This page (NYSE:PLX) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
